GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

BACKGROUND: The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was immune checkpoint inhibitors (ICIs). METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jeong A., Cheung, Nai-Kong V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731630/
https://www.ncbi.nlm.nih.gov/pubmed/33303017
http://dx.doi.org/10.1186/s13045-020-01012-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731630/
https://www.ncbi.nlm.nih.gov/pubmed/33303017
http://dx.doi.org/10.1186/s13045-020-01012-y

Ejemplares similares